The mechanisms in glucose metabolism of aging hippocampus

Abstract

With the intensification of the aging society, the incidence of various neurodegenerative diseases is on the rise. The hippocampus is susceptible to age-related neuronal decline and is the earliest and crucial region affected in the transition from healthy aging to neurodegenerative diseases. Before the diagnosis of neurodegenerative diseases, there is already a decline in brain energy metabolism, with the disruption of energy metabolism serving as the primary mechanism leading to neuronal damage. This triggers complex signaling mechanisms both inside and outside the brain during the aging process. Glucose serves as the primary energy source for brain tissues, and a decrease in glucose metabolism is an early indicator of age-related functional changes in the brain. Therefore, understanding the pathophysiological basis of glucose metabolism in the aging hippocampus, as well as the underlying mechanisms, is crucial in comprehending cognitive aging. Such understanding is integral for early intervention and the mitigation of memory and learning impairments caused by energy metabolism. In this review, we have delved into the characteristics of energy metabolism, focusing specifically on glucose metabolism, as well as exploring the molecular foundations and associated mechanisms present within hippocampal neuronal cells under both normal and aging conditions. Notably, our investigation has highlighted the vital roles played by ALG5 and STT3A, key molecules involved in N-glycosylation, in influencing GLUT expression and the rate of membrane transport, regulating glucose metabolism, and thereby influencing cellular glucose uptake. The exploration of this study direction holds considerable promise for future endeavors.

Keywords

aging / ALG5 / glucose metabolism / hippocampus / STT3A

References

[1] Glisky EL. Changes in cognitive function in human aging. In: Riddle DR, ed. Brain Aging: Models, Methods, and Mechanisms. CRC Press; 2007.

[2] Mattson MP, Arumugam TV. Hallmarks of brain aging: adaptive and pathological modification by metabolic states. Cell Metab. 2018; 27:1176-1199.

[3] Gonzales MM, Garbarino VR, Pollet E, et al. Biological aging processes underlying cognitive decline and neurodegenerative disease. J Clin Invest. 2022; 132:e158453.

[4] Pandya VA, Patani R. Region-specific vulnerability in neurodegeneration: lessons from normal ageing. Ageing Res Rev. 2021; 67:101311.

[5] Diersch N, Valdes-Herrera JP, Tempelmann C, Wolbers T. Increased hippocampal excitability and altered learning dynamics mediate cognitive mapping deficits in human aging. J Neurosci. 2021; 41:3204-3221.

[6] Kalpouzos G, Chételat G, Baron JC, et al. Voxel-based mapping of brain gray matter volume and glucose metabolism profiles in normal aging. Neurobiol Aging. 2009; 30:112-124.

[7] Camandola S, Mattson MP. Brain metabolism in health, aging, and neurodegeneration. EMBO J. 2017; 36:1474-1492.

[8] Zhao J, Tan C, Imai R, et al. Evaluation of organ glucose metabolism by (18)F-FDG accumulation with insulin loading in aged mice compared with young normal mice. Sci Rep. 2021; 11:7421.

[9] Coupé P, Catheline G, Lanuza E, Manjón JV. Towards a unified analysis of brain maturation and aging across the entire lifespan: a MRI analysis. Hum Brain Mapp. 2017; 38:5501-5518.

[10] Mosconi L. Glucose metabolism in normal aging and Alzheimer's disease: methodological and physiological considerations for PET studies. Clin Transl Imaging. 2013; 1:217-233.

[11] McNair LM, Andersen JV, Waagepetersen HS. Stable isotope tracing reveals disturbed cellular energy and glutamate metabolism in hippocampal slices of aged male mice. Neurochem Int. 2023; 171:105626.

[12] Sokoloff L. Energetics of functional activation in neural tissues. Neurochem Res. 1999; 24:321-329.

[13] Hyder F, Rothman DL, Bennett MR. Cortical energy demands of signaling and nonsignaling components in brain are conserved across mammalian species and activity levels. Proc Natl Acad Sci USA. 2013; 110:3549-3554.

[14] Pardridge WM. Brain metabolism: a perspective from the blood-brain barrier. Physiol Rev. 1983; 63:1481-1535.

[15] Nehlig A, Pereira de Vasconcelos A. Glucose and ketone body utilization by the brain of neonatal rats. Prog Neurobiol. 1993; 40:163-220.

[16] van Hall G, Stømstad M, Rasmussen P, et al. Blood lactate is an important energy source for the human brain. J Cereb Blood Flow Metab. 2009; 29:1121-1129.

[17] Du J, Ma M, Zhao Q, et al. Mitochondrial bioenergetic deficits in the hippocampi of rats with chronic ischemia-induced vascular dementia. Neuroscience. 2013; 231:345-352.

[18] Bliss TVP, Collingridge GL. A synaptic model of memory: long-term potentiation in the hippocampus. Nature. 1993; 361:31-39.

[19] Maguire EA, Burgess N, Donnett JG, Frackowiak RSJ, Frith CD, O'Keefe J. Knowing where and getting there: a human navigation network. Science. 1998; 280:921-924.

[20] Vinogradova OS. Hippocampus as comparator: role of the two input and two output systems of the hippocampus in selection and registration of information. Hippocampus. 2001; 11:578-598.

[21] McEwen BS, Eiland L, Hunter RG, Miller MM. Stress and anxiety: structural plasticity and epigenetic regulation as a consequence of stress. Neuropharmacology. 2012; 62:3-12.

[22] Messier C. Glucose improvement of memory: a review. Eur J Pharmacol. 2004; 490:33-57.

[23] Smith MA, Riby LM, Eekelen JAM, Foster JK. Glucose enhancement of human memory: a comprehensive research review of the glucose memory facilitation effect. Neurosci Biobehav Rev. 2011; 35:770-783.

[24] Messier C, White NM. Memory improvement by glucose, fructose, and two glucose analogs: a possible effect on peripheral glucose transport. Behav Neural Biol. 1987; 48:104-127.

[25] Hughes RN. Effects of glucose on responsiveness to change in young adult and middle-aged rats. Physiol Behav. 2003; 78:529-534.

[26] McNay EC, Gold PE. Food for thought: fluctuations in brain extracellular glucose provide insight into the mechanisms of memory modulation. Behav Cogn Neurosci Rev. 2002; 1:264-280.

[27] McNay EC, Fries TM, Gold PE. Decreases in rat extracellular hippocampal glucose concentration associated with cognitive demand during a spatial task. Proc Natl Acad Sci USA. 2000; 97:2881-2885.

[28] de la Monte SM, Tong M, Bowling N, Moskal P. si-RNA inhibition of brain insulin or insulin-like growth factor receptors causes developmental cerebellar abnormalities: relevance to fetal alcohol spectrum disorder. Mol Brain. 2011; 4:13.

[29] De Felice FG, Lourenco MV, Ferreira ST. How does brain insulin resistance develop in Alzheimer's disease? Alzheimer's Dementia. 2014; 10:S26-S32.

[30] Ragozzino ME, Unick KE, Gold PE. Hippocampal acetylcholine release during memory testing in rats: augmentation by glucose. Proc Natl Acad Sci USA. 1996; 93:4693-4698.

[31] Durkin TP, Messier C, de Boer P, Westerink BHC. Raised glucose levels enhance scopolamine-induced acetylcholine overflow from the hippocampus: an in vivo microdialysis study in the rat. Behav Brain Res. 1992; 49:181-188.

[32] Stefani MR, Nicholson GM, Gold PE. ATP-sensitive potassium channel blockade enhances spontaneous alternation performance in the rat: a potential mechanism for glucose-mediated memory enhancement. Neuroscience. 1999; 93:557-563.

[33] Mattay VS, Fera F, Tessitore A, et al. Neurophysiological correlates of age-related changes in working memory capacity. Neurosci Lett. 2006; 392:32-37.

[34] Sowell ER, Peterson BS, Thompson PM, Welcome SE, Henkenius AL, Toga AW. Mapping cortical change across the human life span. Nat Neurosci. 2003; 6:309-315.

[35] Nakamura S, Akiguchi I, Kameyama M, Mizuno N. Age-related changes of pyramidal cell basal dendrites in layers III and V of human motor cortex: a quantitative Golgi study. Acta Neuropathol. 1985; 65:281-284.

[36] Schmidt-Wilcke T, Poljansky S, Hierlmeier S, Hausner J, Ibach B. Memory performance correlates with gray matter density in the ento-/perirhinal cortex and posterior hippocampus in patients with mild cognitive impairment and healthy controls–a voxel based morphometry study. Neuroimage. 2009; 47:1914-1920.

[37] Simpson IA, Chundu KR, Davies-Hill T, Honer WG, Davies P. Decreased concentrations of GLUT1 and GLUT3 glucose transporters in the brains of patients with Alzheimer's disease. Ann Neurol. 1994; 35:546-551.

[38] Piert M, Koeppe RA, Giordani B, Berent S, Kuhl DE. Diminished glucose transport and phosphorylation in Alzheimer's disease determined by dynamic FDG-PET. J Nuclear Med. 1996; 37:201-208.

[39] Mosconi L, De Santi S, Li J, et al. Hippocampal hypometabolism predicts cognitive decline from normal aging. Neurobiol Aging. 2008; 29:676-692.

[40] Zuendorf G, Kerrouche N, Herholz K, Baron JC. Efficient principal component analysis for multivariate 3D voxel-based mapping of brain functional imaging data sets as applied to FDG-PET and normal aging. Hum Brain Mapp. 2003; 18:13-21.

[41] Jagust W, Gitcho A, Sun F, Kuczynski B, Mungas D, Haan M. Brain imaging evidence of preclinical Alzheimer's disease in normal aging. Ann Neurol. x2006; 59(4):673-681.

[42] Hamberger A, Hydén H. Inverse enzymatic changes in neurons and glia during increased function and hypoxia. J Cell Biol. 1963; 16:521-525.

[43] Ramsey RB, Jones JP, Naqvi SHM, Nicholas HJ. The biosynthesis of cholesterol and other sterols by brain tissue. I. subcellular biosynthesis in vitro. Lipids. 1971; 6:154-161.

[44] Gaitonde MK, Richter D. Changes with age in the utilization of glucose carbon in liver and brain. J Neurochem. 1966; 13:1309-1318.

[45] Gaitonde MK, Evison E, Evans GM. The rate of utilization of glucose via hexosemonophosphate shunt in brain. J Neurochem. 1983; 41:1253-1260.

[46] Stincone A, Prigione A, Cramer T, et al. The return of metabolism: biochemistry and physiology of the pentose phosphate pathway. Biol Rev. 2015; 90:927-963.

[47] Craft S, Dagogo-Jack SE, Wiethop BV, et al. Effects of hyperglycemia on memory and hormone levels in dementia of the Alzheimer type: a longitudinal study. Behav Neurosci. 1993; 107:926-940.

[48] Craft S, Newcomer J, Kanne S, et al. Memory improvement following induced hyperinsulinemia in Alzheimer's disease. Neurobiol Aging. 1996; 17:123-130.

[49] Bingham EM, Hopkins D, Smith D, et al. The role of insulin in human brain glucose metabolism. Diabetes. 2002; 51:3384-3390.

[50] Cholerton B, Baker LD, Craft S. Insulin resistance and pathological brain ageing. Diabetic Med. 2011; 28:1463-1475.

[51] Błaszczyk JW. Energy metabolism decline in the aging brain-pathogenesis of neurodegenerative disorders. Metabolites. 2020; 10:450.

[52] Goyal MS, Vlassenko AG, Blazey TM, et al. Loss of brain aerobic glycolysis in normal human aging. Cell Metab. 2017; 26:353-360.

[53] Deng D, Yan N. GLUT, SGLT, and SWEET: structural and mechanistic investigations of the glucose transporters. Prot Sci. 2016; 25:546-558.

[54] Bell GI, Burant CF, Takeda J, Gould GW. Structure and function of mammalian facilitative sugar transporters. J Biol Chem. 1993; 268:19161-19164.

[55] Vannucci SJ, Maher F, Simpson IA. Glucose transporter proteins in brain: delivery of glucose to neurons and glia. GLIA. 1997; 21:2-21.

[56] Vorbrodt AW, Dobrogowska DH, Tarnawski M. Immunogold study of interendothelial junction-associated and glucose transporter proteins during postnatal maturation of the mouse blood-brain barrier. J Neurocytol. 2001; 30:705-716.

[57] Doege H, Bocianski A, Joost HG, Schürmann A. Activity and genomic organization of human glucose transporter 9 (GLUT9), a novel member of the family of sugar-transport facilitators predominantly expressed in brain and leucocytes. Biochem J. 2000; 350(Pt 3):771-776.

[58] Ibberson M, Riederer BM, Uldry M, Guhl B, Roth J, Thorens B. Immunolocalization of GLUTX1 in the testis and to specific brain areas and vasopressin-containing neurons. Endocrinology. 2002; 143:276-284.

[59] Carruthers A, DeZutter J, Ganguly A, Devaskar SU. Will the original glucose transporter isoform please stand up! Am J Physiol Endocrinol Metab. 2009; 297:E836-E848.

[60] Sakyo T, Naraba H, Teraoka H, Kitagawa T. The intrinsic structure of glucose transporter isoforms Glut1 and Glut3 regulates their differential distribution to detergent-resistant membrane domains in nonpolarized mammalian cells. FEBS J. 2007; 274:2843-2853.

[61] Deng D, Xu C, Sun P, et al. Crystal structure of the human glucose transporter GLUT1. Nature. 2014; 510:121-125.

[62] Rees DC. Powering brain power: GLUT1 and the era of structure based human transporter biology. Natl Sci Rev. 2015; 2:3-4.

[63] Saab AS, Tzvetavona ID, Trevisiol A, et al. Oligodendroglial NMDA receptors regulate glucose import and axonal energy metabolism. Neuron. 2016; 91:119-132.

[64] Magistretti PJ, Allaman I. Lactate in the brain: from metabolic end-product to signalling molecule. Nat Rev Neurosci. 2018; 19:235-249.

[65] Mason S. Lactate shuttles in neuroenergetics-homeostasis, allostasis and beyond. Front Neurosci. 2017; 11:43.

[66] Koepsell H. Glucose transporters in brain in health and disease. Pflügers Archiv Eur J Physiol. 2020; 472(9):1299-1343.

[67] Winkler EA, Nishida Y, Sagare AP, et al. GLUT1 reductions exacerbate Alzheimer's disease vasculo-neuronal dysfunction and degeneration. Nature Neurosci. 2015; 18:521-530.

[68] Nakamura S, Muramatsu S, Takino N, et al. Gene therapy for Glut1-deficient mouse using an adeno-associated virus vector with the human intrinsic GLUT1 promoter. J Gene Med. 2018; 20:e3013.

[69] Augustin R. The protein family of glucose transport facilitators: it's not only about glucose after all. IUBMB Life. 2010; 62:315-333.

[70] McCall AL, Van Bueren AM, Moholt-Siebert M, Cherry NJ, Woodward WR. Immunohistochemical localization of the neuron-specific glucose transporter (GLUT3) to neuropil in adult rat brain. Brain Res. 1994; 659:292-297.

[71] Colville CA, Seatter MJ, Jess TJ, Gould GW, Thomas HM. Kinetic analysis of the liver-type (GLUT2) and brain-type (GLUT3) glucose transporters in Xenopus oocytes: substrate specificities and effects of transport inhibitors. Biochem J. 1993; 290(Pt 3):701-706.

[72] Mantych GJ, James DE, Chung HD, Devaskar SU. Cellular localization and characterization of Glut 3 glucose transporter isoform in human brain. Endocrinology. 1992; 131:1270-1278.

[73] Stuart Wood I, Wang B, Lorente-Cebrián S, Trayhurn P. Hypoxia increases expression of selective facilitative glucose transporters (GLUT) and 2-deoxy-D-glucose uptake in human adipocytes. Biochem Biophys Res Commun. 2007; 361:468-473.

[74] Korgun ET, Demir R, Sedlmayr P, et al. Sustained hypoglycemia affects glucose transporter expression of human blood leukocytes. Blood Cells Mol Dis. 2002; 28:152-159.

[75] Peng W, Tan C, Mo L, et al. Glucose transporter 3 in neuronal glucose metabolism: health and diseases. Metabolism. 2021; 123:154869.

[76] von Leden RE, Moritz KE, Bermudez S, et al. Aging alters glucose uptake in the naïve and injured rodent spinal cord. Neurosci Lett. 2019; 690:23-28.

[77] Fattoretti P, BERTONI-FREDDARI C, Casoli T, Di Stefano G, Giorgetti G, Solazzi M. Ethanol-induced decrease of the expression of glucose transport protein (Glut3) in the central nervous system as a predisposing condition to apoptosis: the effect of age. Ann NY Acad Sci. 2003; 1010:500-503.

[78] Gamberino WC, Brennan, Jr. WA. Glucose transporter isoform expression in Huntington's disease brain. J Neurochem. 1994; 63:1392-1397.

[79] Covarrubias-Pinto A, Moll P, Solís-Maldonado M, et al. Beyond the redox imbalance: oxidative stress contributes to an impaired GLUT3 modulation in Huntington's disease. Free Radic Biol Med. 2015; 89:1085-1096.

[80] Liu Y, Liu F, Iqbal K, Grundke-Iqbal I, Gong CX. Decreased glucose transporters correlate to abnormal hyperphosphorylation of tau in Alzheimer disease. FEBS Lett. 2008; 582:359-364.

[81] An Y, Varma VR, Varma S, et al. Evidence for brain glucose dysregulation in Alzheimer's disease. Alzheimer's Dementia. 2018; 14:318-329.

[82] Piroli GG, Grillo CA, Reznikov LR, et al. Corticosterone impairs insulin-stimulated translocation of GLUT4 in the rat hippocampus. Neuroendocrinology. 2007; 85:71-80.

[83] Vannucci SJ, Koehler-Stec EM, Li K, Reynolds TH, Clark R, Simpson IA. GLUT4 glucose transporter expression in rodent brain: effect of diabetes. Brain Res. 1998; 797:1-11.

[84] Ashrafi G, Wu Z, Farrell RJ, Ryan TA. GLUT4 mobilization supports energetic demands of active synapses. Neuron. 2017; 93:606-615.

[85] Hou JC, Suzuki N, Pessin JE, Watson RT. A specific dileucine motif is required for the GGA-dependent entry of newly synthesized insulin-responsive aminopeptidase into the insulin-responsive compartment. J Biol Chem. 2006; 281:33457-33466.

[86] Martinez-Arca S, Lalioti VS, Sandoval IV. Intracellular targeting and retention of the glucose transporter GLUT4 by the perinuclear storage compartment involves distinct carboxyl-tail motifs. J Cell Sci. 2000; 113(Pt 10):1705-1715.

[87] Al-Hasani H, Kunamneni RK, Dawson K, Hinck CS, Müller-Wieland D, Cushman SW. Roles of the N- and C-termini of GLUT4 in endocytosis. J Cell Sci. 2002; 115:131-140.

[88] Yuan Y, Kong F, Xu H, Zhu A, Yan N, Yan C. Cryo-EM structure of human glucose transporter GLUT4. Nat Commun. 2022; 13:2671.

[89] Larance M, Ramm G, James DE. The GLUT4 code. Mol Endocrinol. 2008; 22:226-233.

[90] Pearson-Leary J, McNay EC. Novel roles for the insulin-regulated glucose transporter-4 in hippocampally dependent memory. J Neurosci. 2016; 36:11851-11864.

[91] Kobayashi M, Nikami H, Morimatsu M, Saito M. Expression and localization of insulin-regulatable glucose transporter (GLUT4) in rat brain. Neurosci Lett. 1996; 213:103-106.

[92] Leloup C, Arluison M, Kassis N, et al. Discrete brain areas express the insulin-responsive glucose transporter GLUT4. Mol Brain Res. 1996; 38:45-53.

[93] Chen Z, Zhong C. Decoding Alzheimer's disease from perturbed cerebral glucose metabolism: implications for diagnostic and therapeutic strategies. Prog Neurobiol. 2013; 108:21-43.

[94] Oliveira LT, Leon GVO, Provance Jr. DW, de Mello FG, Sorenson MM, Salerno VP. Exogenous β-amyloid peptide interferes with GLUT4 localization in neurons. Brain Res. 2015; 1615:42-50.

[95] Wang L, Hall C, Li J, Choi E, Bai X. Structural basis of the alkaline pH-dependent activation of insulin receptor-related receptor. Nat Struct Mol Biol. 2023; 30:661-669.

[96] Czech MP. The nature and regulation of the insulin receptor: structure and function. Annu Rev Physiol. 1985; 47:357-381.

[97] Ye L, Maji S, Sanghera N, et al. Structure and dynamics of the insulin receptor: implications for receptor activation and drug discovery. Drug Discovery Today. 2017; 22:1092-1102.

[98] Seino S, Seino M, Nishi S, Bell GI. Structure of the human insulin receptor gene and characterization of its promoter. Proc Natl Acad Sci. 1989; 86:114-118.

[99] Arnold SE, Arvanitakis Z, Macauley-Rambach SL, et al. Brain insulin resistance in type 2 diabetes and Alzheimer disease: concepts and conundrums. Nat Rev Neurol. 2018; 14:168-181.

[100] Denver P, McClean P. Distinguishing normal brain aging from the development of Alzheimer's disease: inflammation, insulin signaling and cognition. Neural Regen Res. 2018; 13:1719-1730.

[101] De Meyts P. Insulin/receptor binding: the last piece of the puzzle? What recent progress on the structure of the insulin/receptor complex tells us (or not) about negative cooperativity and activation. BioEssays. 2015; 37:389-397.

[102] Adams TE, Epa VC, Garrett TPJ, Ward* CW. Structure and function of the type 1 insulin-like growth factor receptor. Cell Mol Life Sci. 2000; 57:1050-1093.

[103] Roith DL, Scavo L, Butler A. What is the role of circulating IGF-I? Trends Endocrinol Metab. 2001; 12:48-52.

[104] Liu JP, Baker J, Perkins AS, Robertson EJ, Efstratiadis A. Mice carrying null mutations of the genes encoding insulin-like growth factor I (Igf-1) and type 1 IGF receptor (Igf1r). Cell. 1993; 75:59-72.

[105] Carro E, Trejo JL, Spuch C, Bohl D, Heard JM, Torres-Aleman I. Blockade of the insulin-like growth factor I receptor in the choroid plexus originates Alzheimer's-like neuropathology in rodents: new cues into the human disease? Neurobiol Aging. 2006; 27:1618-1631.

[106] Suh Y, Atzmon G, Cho MO, et al. Functionally significant insulin-like growth factor I receptor mutations in centenarians. Proc Natl Acad Sci. 2008; 105:3438-3442.

[107] Freeze HH, Chong JX, Bamshad MJ, Ng BG. Solving glycosylation disorders: fundamental approaches reveal complicated pathways. Am J Hum Genet. 2014; 94:161-175.

[108] Casalino L, Gaieb Z, Goldsmith JA, et al. Beyond shielding: the roles of glycans in SARS-CoV-2 spike proteian. ACS Cent Sci. 2020; 6(10):1722-1734.

[109] Ramírez Hernández E, Hernández-Zimbrón LF, Martínez Zúñiga N, et al. The role of the SARS-CoV-2 S-protein glycosylation in the interaction of SARS-CoV-2/ACE2 and immunological responses. Viral Immunol. 2021; 34:165-173.

[110] Schmidt JW, Catterall WA. Palmitylation, sulfation, and glycosylation of the alpha subunit of the sodium channel. Role of post-translational modifications in channel assembly. J Biol Chem. 1987; 262:13713-13723.

[111] Guo HB, Johnson H, Randolph M, Pierce M. Regulation of homotypic cell-cell adhesion by branched N-glycosylation of N-cadherin extracellular EC2 and EC3 domains. J Biol Chem. 2009; 284:34986-34997.

[112] Albach C, Damoc E, Denzinger T, Schachner M, Przybylski M, Schmitz B. Identification of N-glycosylation sites of the murine neural cell adhesion molecule NCAM by MALDI-TOF and MALDI-FTICR mass spectrometry. Anal Bioanal Chem. 2004; 378:1129-1135.

[113] Torre ER, Steward O. Protein synthesis within dendrites: glycosylation of newly synthesized proteins in dendrites of hippocampal neurons in culture. J Neurosci. 1996; 16:5967-5978.

[114] Marquardt T, Denecke J. Congenital disorders of glycosylation: review of their molecular bases, clinical presentations and specific therapies. Eur J Pediatr. 2003; 162:359-379.

[115] Freeze HH, Aebi M. Altered glycan structures: the molecular basis of congenital disorders of glycosylation. Curr Opin Struct Biol. 2005; 15:490-498.

[116] Bradberry MM, Peters-Clarke TM, Shishkova E, Chapman ER, Coon JJ. N-glycoproteomics of brain synapses and synaptic vesicles. Cell Rep. 2023; 42(4):112368.

[117] Inaba H, Kai D, Kida S. N-glycosylation in the hippocampus is required for the consolidation and reconsolidation of contextual fear memory. Neurobiol Learn Mem. 2016; 135:57-65.

[118] Matthies Jr. H, Kretlow J, Matthies H, Smalla KH, Staak S, Krug M. Glycosylation of proteins during a critical time window is necessary for the maintenance of long-term potentiation in the hippocampal CA1 region. Neuroscience. 1999; 91:175-183.

[119] Fiedler K, Simons K. The role of N-glycans in the secretory pathway. Cell. 1995; 81:309-312.

[120] Kumagai AK, Dwyer KJ, Pardridge WM. Differential glycosylation of the GLUT1 glucose transporter in brain capillaries and choroid plexus. Biochim Biophys Acta. 1994; 1193:24-30.

[121] Birnbaum MJ, Haspel HC, Rosen OM. Cloning and characterization of a cDNA encoding the rat brain glucose-transporter protein. Proc Natl Acad Sci. 1986; 83:5784-5788.

[122] Harada Y, Hirayama H, Suzuki T. Generation and degradation of free asparagine-linked glycans. Cell Mol Life Sci. 2015; 72:2509-2533.

[123] Harada Y, Ohkawa Y, Kizuka Y, Taniguchi N. Oligosaccharyltransferase: a gatekeeper of health and tumor progression. Int J Mol Sci. 2019; 20:6074.

[124] Heesen S, Lehle L, Weissmann A, Aebi M. Isolation of the ALG5 locus encoding the UDP-glucose:dolichyl-phosphate glucosyltransferase from Saccharomyces cerevisiae. Eur J Biochem. 1994; 224:71-79.

[125] Larkin A, Chang MM, Whitworth GE, Imperiali B. Biochemical evidence for an alternate pathway in N-linked glycoprotein biosynthesis. Nat Chem Biol. 2013; 9:367-373.

[126] Runge KW, Huffaker TC, Robbins PW. Two yeast mutations in glucosylation steps of the asparagine glycosylation pathway. J Biol Chem. 1984; 259:412-417.

[127] Shaik KS, Pabst M, Schwarz H, Altmann F, Moussian B. The Alg5 ortholog Wollknäuel is essential for correct epidermal differentiation during Drosophila late embryogenesis. Glycobiology. 2011; 21:743-756.

[128] Kelleher DJ, Karaoglu D, Mandon EC, Gilmore R. Oligosaccharyltransferase isoforms that contain different catalytic STT3 subunits have distinct enzymatic properties. Mol Cell. 2003; 12:101-111.

[129] Shrimal S, Cherepanova NA, Gilmore R. DC2 and KCP2 mediate the interaction between the oligosaccharyltransferase and the ER translocon. J Cell Biol. 2017; 216:3625-3638.

[130] Wen P, Chen J, Zuo C, Gao X, Fujita M, Yang G. Proteome and glycoproteome analyses reveal the protein N-linked glycosylation specificity of STT3A and STT3B. Cells. 2022; 11:2775.

[131] Wang P, He C, Yue M, et al. The AT1 receptor autoantibody causes hypoglycemia in fetal rats via promoting the STT3A-GLUT1-glucose uptake axis in liver. Mol Cell Endocrinol. 2020; 518:111022.

[132] Zhang S, Lachance BB, Mattson MP, Jia X. Glucose metabolic crosstalk and regulation in brain function and diseases. Prog Neurobiol. 2021; 204:102089.

[133] Boucher J, Kleinridders A, Kahn CR. Insulin receptor signaling in normal and insulin-resistant states. Cold Spring Harbor Perspect Biol. 2014; 6:a009191.

[134] Zhang L, Huang Y, Sun J, et al. Protective effects of calorie restriction on insulin resistance and islet function in STZ-induced type 2 diabetes rats. Nutr Metab (Lond). 2021; 18(1):48.

[135] Grillo CA, Piroli GG, Hendry RM, Reagan LP. Insulin-stimulated translocation of GLUT4 to the plasma membrane in rat hippocampus is PI3-kinase dependent. Brain Res. 2009; 1296:35-45.

[136] Griffith CM, Eid T, Rose GM, Patrylo PR. Evidence for altered insulin receptor signaling in Alzheimer's disease. Neuropharmacology. 2018; 136:202-215.

[137] Becker AB, Roth RA. Insulin receptor structure and function in normal and pathological conditions. Annu Rev Med. 1990; 41:99-115.

[138] Craft S, Claxton A, Baker LD, et al. Effects of regular and long-acting insulin on cognition and Alzheimer's disease biomarkers: a pilot clinical trial. J Alzheimer's Dis. 2017; 57:1325-1334.

[139] Duarte AI, Santos MS, Oliveira CR, Moreira PI. Brain insulin signalling, glucose metabolism and females' reproductive aging: a dangerous triad in Alzheimer's disease. Neuropharmacology. 2018; 136:223-242.

[140] Cunnane SC, Trushina E, Morland C, et al. Brain energy rescue: an emerging therapeutic concept for neurodegenerative disorders of ageing. Nat Rev Drug Discovery. 2020; 19:609-633.

[141] Beurel E, Grieco SF, Jope RS. Glycogen synthase kinase-3 (GSK3): regulation, actions, and diseases. Pharmacol Ther. 2015; 148:114-131.

[142] Yang L, Wang H, Liu L, Xie A. The role of Insulin/IGF-1/PI3K/Akt/GSK3β signaling in Parkinson's disease dementia. Front Neurosci. 2018; 12:73.

[143] Minhas PS, Latif-Hernandez A, McReynolds MR, et al. Restoring metabolism of myeloid cells reverses cognitive decline in ageing. Nature. 2021; 590:122-128.

[144] Rothman DL, Dienel GA, Behar KL, et al. Glucose sparing by glycogenolysis (GSG) determines the relationship between brain metabolism and neurotransmission. J Cereb Blood Flow Metab. 2022; 42:844-860.

[145] Lin SC, Hardie DG. AMPK: sensing glucose as well as cellular energy status. Cell Metab. 2018; 27:299-313.

[146] Herzig S, Shaw RJ. AMPK: guardian of metabolism and mitochondrial homeostasis. Nat Rev Mol Cell Biol. 2018; 19:121-135.

[147] Li S, Sheng ZH. Energy matters: presynaptic metabolism and the maintenance of synaptic transmission. Nat Rev Neurosci. 2022; 23:4-22.

[148] Sakamoto K, Holman GD. Emerging role for AS160/TBC1D4 and TBC1D1 in the regulation of GLUT4 traffic. Am J Physiol Endocrinol Metab. 2008; 295:E29-E37.

[149] Oyarzabal A, Marin-Valencia I. Synaptic energy metabolism and neuronal excitability, in sickness and health. J Inherit Metab Dis. 2019; 42:220-236.

[150] Carroll RC, Zukin RS. NMDA-receptor trafficking and targeting: implications for synaptic transmission and plasticity. Trends Neurosci. 2002; 25:571-577.

[151] Gozlan H. NMDA receptor redox sites: are they targets for selective neuronal protection? Trends Pharmacol Sci. 1995; 16:368-374.

[152] Rameau GA, Tukey DS, Garcin-Hosfield ED, et al. Biphasic coupling of neuronal nitric oxide synthase phosphorylation to the NMDA receptor regulates AMPA receptor trafficking and neuronal cell death. J Neurosci. 2007; 27:3445-3455.

[153] Ferreira JM, Burnett AL, Rameau GA. Activity-dependent regulation of surface glucose transporter-3. J Neurosci. 2011; 31:1991-1999.

[154] Serulle Y, Zhang S, Ninan I, et al. A GluR1-cGKII interaction regulates AMPA receptor trafficking. Neuron. 2007; 56:670-688.

[155] Cidad P, Almeida A, Bolaños JP. Inhibition of mitochondrial respiration by nitric oxide rapidly stimulates cytoprotective GLUT3-mediated glucose uptake through 5’-AMP-activated protein kinase. Biochem J. 2004; 384:629-636.

[156] Uemura E, Greenlee HW. Amyloid β-peptide inhibits neuronal glucose uptake by preventing exocytosis. Exp Neurol. 2001; 170:270-276.

[157] Uemura E, Greenlee HW. Insulin regulates neuronal glucose uptake by promoting translocation of glucose transporter GLUT3. Exp Neurol. 2006; 198:48-53.

[158] Chen J, Park CS, Tang SJ. Activity-dependent synaptic Wnt release regulates hippocampal long term potentiation. J Biol Chem. 2006; 281:11910-11916.

[159] Cerpa W, Godoy JA, Alfaro I, et al. Wnt-7a modulates the synaptic vesicle cycle and synaptic transmission in hippocampal neurons. J Biol Chem. 2008; 283:5918-5927.

[160] Inestrosa NC, Arenas E. Emerging roles of Wnts in the adult nervous system. Nat Rev Neurosci. 2010; 11:77-86.

[161] Ciani L, Salinas PC. WNTs in the vertebrate nervous system: from patterning to neuronal connectivity. Nat Rev Neurosci. 2005; 6:351-362.

[162] Silva-Alvarez C, Arrázola MS, Godoy JA, Ordenes D, Inestrosa NC. Canonical Wnt signaling protects hippocampal neurons from Aβ oligomers: role of non-canonical Wnt-5a/Ca(2+) in mitochondrial dynamics. Front Cell Neurosci. 2013; 7:97.

[163] Cisternas P, Salazar P, Silva-Álvarez C, Barros LF, Inestrosa NC. Wnt5a increases the glycolytic rate and the activity of the pentose phosphate pathway in cortical neurons. Neural Plast. 2016; 2016:9839348.

[164] Jin T, George Fantus I, Sun J. Wnt and beyond Wnt: multiple mechanisms control the transcriptional property of β-catenin. Cell Signal. 2008; 20:1697-1704.

[165] Shao W, Wang D, Chiang YT, et al. The Wnt signaling pathway effector TCF7L2 controls gut and brain proglucagon gene expression and glucose homeostasis. Diabetes. 2013; 62:789-800.

[166] Jedrychowski MP, Gartner CA, Gygi SP, et al. Proteomic analysis of GLUT4 storage vesicles reveals LRP1 to be an important vesicle component and target of insulin signaling. J Biol Chem. 2010; 285:104-114.

[167] Liu CC, Hu J, Tsai CW, et al. Neuronal LRP1 regulates glucose metabolism and insulin signaling in the brain. J Neurosci. 2015; 35:5851-5859.

[168] Lodge EK, Bell JD, Roloff EM, Hamilton KE, Louters LL, Looyenga BD. Pharmacologic inhibition of N-linked glycan trimming with kifunensine disrupts GLUT1 trafficking and glucose uptake. Biochimie. 2020; 174:18-29.

[169] Asano T, Takata K, Katagiri H, et al. The role of N-glycosylation in the targeting and stability of GLUT1 glucose transporter. FEBS Lett. 1993; 324:258-261.

[170] Asano T, Katagiri H, Takata K, et al. The role of N-glycosylation of GLUT1 for glucose transport activity. J Biol Chem. 1991; 266:24632-24636.

[171] Scott H, Panin VM. N-glycosylation in regulation of the nervous system. Adv Neurobiol. 2014; 9:367-394.

[172] Haga Y, Ishii K, Suzuki T. N-glycosylation is critical for the stability and intracellular trafficking of glucose transporter GLUT4. J Biol Chem. 2011; 286:31320-31327.

[173] Hirayama S, Hori Y, Benedek Z, Suzuki T, Kikuchi K. Fluorogenic probes reveal a role of GLUT4 N-glycosylation in intracellular trafficking. Nat Chem Biol. 2016; 12:853-859.

RIGHTS & PERMISSIONS

2025 The Author(s). Ibrain published by Affiliated Hospital of Zunyi Medical University (AHZMU) and Wiley-VCH GmbH.